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Abstract
Azole resistant fungal infections remain a health problem for the immune compromised.
Current therapies are limited due to rises in new resistance mechanisms. Therefore, it is
important to identify new drug targets for drug discovery and novel therapeutics. Arv1 (are1
are2 required for viability 1) function is highly conserved between multiple pathogenic fungal
species. Candida albicans (C. albicans) cells lacking CaArv1 are azole hypersusceptible
and lack virulence. Saccharomyces cerevisiae (S. cerevisiae) Scarv1 cells are also azole
hypersusceptible, a phenotype reversed by expression of CaArv1, indicating conservation
in the molecular mechanism for azole susceptibility. To define the relationship between Arv1
function and azole susceptibility, we undertook a structure/function analysis of ScArv1. We
identified several conserved amino acids within the ScArv1 homology domain (ScAhd)
required for maintaining normal azole susceptibility. Erg11 lanosterol 14-α-demethylase is
the rate-limiting enzyme in sterol biosynthesis and is the direct target of azole antifungals,
so we used our ScArv1 mutants in order to explore the relationship between ScArv1 and
ScErg11. Specific ScArv1 mutants ectopically expressed from a low copy plasmid were
unable to restore normal azole susceptibility to Scarv1 cells and had reduced Erg11 protein
levels. Erg11 protein stability depended on its ability to form a heterodimeric complex with
Arv1. Complex formation was required for maintaining normal azole susceptibility. Scarv1
cells expressing orthologous CaArv1 mutants also had reduced CaErg11 levels, were
unable to form a CaArv1-CaErg11 complex, and were azole hypersusceptible. Scarv1 cells
expressing CaArv1 mutants unable to interact with CaErg11 could not sustain proper levels
of the azole resistant CaErg11Y132F F145L protein. Caarv1/Caarv1 cells expressing CaArv1
mutants unable to interact with CaErg11 were found to lack virulence using a disseminated
candidiasis mouse model. Expressing CaErg11Y132F F145L did not reverse the lack of viru-
lence. We hypothesize that the role of Arv1 in Erg11-dependent azole resistance is to stabi-
lize Erg11 protein level. Arv1 inhibition may represent an avenue for treating azole
resistance.
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Introduction
Azole antifungal drug resistance continues to be a major morbidity factor for the immune
compromised [1]. In addition to C. albicans infections, an increasing number of azole resistant
non-albicans Candida spp. are being identified in the clinic [1]. These include Candida glab-
rata, Candida parapsilosis, Candida krusei, and Candida tropicalis [2]. While the number of
fungal infections attributed to C. albicans has plateaued, infections caused by these other Can-
dida spp. continue to rise. It has been estimated that ~30–60% of azole resistant fungal infec-
tions are caused by non-albicans Candida spp. [3, 4], underscoring the need to identify
alternative ways to treat azole resistant fungi.
The yeast ergosterol biosynthetic pathway is highly conserved, composed of almost 30
genes, and is housed within the ER [5]. The elegant work of the Bard laboratory strongly sug-
gests that a large ER-localized ergosome complex exists, which harbors multiple protein-pro-
tein interactions that are required for proper sterol synthesis [6]. It is known that ergosterol
synthesis is upregulated in the presence of azole antifungal drugs. This is due to the increased
transcriptional activity of the Upc2 transcription factor [5]. Interestingly, mutations have been
identified in UPC2 in resistant clinical isolates [7]. Presently, the post-translational modifica-
tions regulating ergosterol synthesis are poorly understood. in vitro proteomic data suggest
that several Erg proteins are ubiquitinated [8]. Whether ubiquitination promotes proteosome
degradation has yet to be explored. There is a single report that has suggested there may be a
relationship between the SLT2 mitogen activated kinase and sterol biosynthesis [9].
Azoles drugs block ergosterol biosynthesis in all yeast species [10]. The Erg11 lanosterol 14-
α-demethylase enzymatic reaction is rate-limiting step in ergosterol biosynthesis. Erg11 itself
is the direct target of the azole antifungal drugs [11]. It is highly conserved among pathogenic
and non-pathogenic fungi [12]. It is well established that overexpressing CaERG11 leads to
azole resistance, as well as, mutations that alter Erg11 azole binding affinity [13–15]. Mutations
in Erg11 that reduce azole binding affinity, and thus increase azole resistance, have been
mapped and characterized. All mutations cluster around three regions of the CaErg11 protein:
105–165, 266–287, and 405–488 [16, 17]. Orthologous Erg11 azole resistance mutations have
also been mapped in non-albicans Candida spp. [18].
The loss of the S. cerevisiae Are1 and Are2 acyl-CoA:sterol acyltransferases responsible for
the synthesis of ergosteryl esters results in accumulation of unesterified sterol, but cells remain
viable [19–21], whereas the loss of ARV1 (are1 are2 required for viability 1) in the same back-
ground results in inviability [22]. Arv1 is a three transmembrane protein that contains an
Arv1 homology domain (Ahd)1 that is highly conserved across fungal species (Fig 1A; Ahd,
shaded gray) [23]. Within the AHD is a conserved putative zinc-binding motif that contains
two CXXC motifs separated by ~20 amino acids (Fig 1A; black line) [23, 24].
The exact function of Arv1 has yet to be elucidated, but phenotypes that are associated with
its loss suggest roles in regulating global lipid homeostasis. Scarv1 cells are temperature sensi-
tive and harbor pleiotrophic phenotypes that include azole hypersusceptibility [25], defects in
sterol synthesis and localization that cause the accumulation of the Erg11 substrate lanosterol
[26], and defects in phospholipid [26], sphingolipid [26], and glycosylphosphatidylinositol
homeostasis [27]. It is also known that Scarv1 cells have ER morphology defects and misloca-
lize proteins residing within this organelle [28], have an activated unfolded protein response
(UPR) [29], and are hypersensitive to fatty acid supplementation [30].
Here, we used a structure/function approach to identify conserved amino acids within
ScArv1 that were required for maintaining normal azole drug susceptibility. We uncovered
several amino acid residues within the ScAhd. Scarv1 cells expressing these specific mutant
proteins were hypersusceptible to azole antifungals and had defects in sterol synthesis and
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localization. Mutant strains had reduced levels of ScErg11, most likely due to accelerated pro-
teosomal degradation. Interestingly, we uncovered a physical interaction between ScArv1 and
ScErg11 that was lost in azole hypersusceptible mutants. Identical results were recapitulated in
Scarv1 cells expressing orthologous CaArv1 mutants. Finally, we found that Caarv1/Caarv1
strains expressing hypersusceptible CaArv1 mutants that lacked the ability to interact with
CaErg11 lacked virulence. Overall our work suggests a direct correlation between Arv1 func-
tion and virulence. This may be due to it functioning in the maintenance of Erg11 stability.
Thus, establishing a functional Erg11-Arv1 complex may be important for maintaining the vir-
ulence of C. albicans.
Results
Full-length Arv1 is required for maintaining normal antifungal
susceptibility
Tinkelenberg et al., [22] showed that Scarv1 cells were hypersusceptible to the polyene antifun-
gal, nystatin. We previously showed that Scarv1 cells were also hypersusceptible to azole anti-
fungals [25]. In order to delineate what portions of ScArv1 were required for normal azole
susceptibility, we ectopically expressed full-length Arv1-HA (Arv1-HA), Ahd-HA (Ahd-HA)
alone, or an Arv1 protein lacking the Ahd (ΔAhd-HA) from the endogenous ScARV1 pro-
moter using a low copy centromeric plasmid. We then tested whether these truncations were
able to confer normal antifungal susceptibility to Scarv1 cells.
Fig 1. Amino acid sequence alignments of fungal Arv1 and Erg11 proteins. (A) Amino acid sequences of Arv1 proteins from S. cerevisiae, C. albicans,
C. glabrata, C. parapsilosis, and C. tropicalis. Ahd (shaded gray); zinc-binding motif (black line); conserved amino acids (lower row); transmembrane
domains (orange line); asterisks, (mutated amino acids). All sequences start at amino acid 3. (B) Fungal Erg11 amino acid sequences are shown
containing conserved Tyr and Phe residues (shaded gray).
https://doi.org/10.1371/journal.pone.0235746.g001
PLOS ONE Arv1 and azole resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0235746 July 17, 2020 3 / 31
Our western analysis did indicate that the Ahd-HA and ΔAhd-HA proteins were expressed
to lower levels then Arv1-HA (Fig 2A & 2B). It has been shown previously that Scarv1 cells
expressing the ΔAhd retain some Arv1 functions [31].
We used the antifungal drugs itraconazole, fluconazole, lovastatin, fenpropimorph, and ter-
binafine. A subset of these antifungals targets the Erg11 reaction in the ergosterol biosynthetic
pathway (itraconazole and fluconazole), as well as reactions upstream (lovastatin) and down-
stream (fenpropimorph, and terbinafine) of Erg11.
We found that Scarv1 cells were hypersusceptible to itraconazole and fluconazole azole antifun-
gal drugs (Table 1). These cells were also hypersusceptible to terbinafine and fenpropimorph,
while showing normal susceptibility to lovastatin (Table 1). Scarv1 cells expressing ScAhd or
ScΔAhd had similar susceptibility profiles. Wild type and Scarv1 cells expressing full-length
ScArv1 showed normal susceptibility to all antifungal drugs tested. Thus, neither the ScAhd nor
ScΔAhd could replace full-length ScArv1 and restore normal antifungal susceptibility to Scarv1
cells treated with several antifungal drugs, which target different steps in the ergosterol biosynthetic
pathway. We point out that normal susceptibility to lovastatin seems reasonable, as this antifungal
drug targets HMG-CoA reductase, which is an enzyme upstream of the Erg11 enzymatic step.
Conserved amino acids within the Ahd are required for maintaining
normal antifungal susceptibility
The amino acid sequence alignments of Arv1 proteins from S. cerevisiae, C. albicans, C. glab-
rata, C. parapsilosis, and C. tropicalis are shown (Fig 1A). 25 conserved amino acid residues
were found within the Ahd’s of these species (bottom row). No homology was found outside
the ScAhd. Thus, we focused on identifying conserved amino acids within the ScAhd that
were required for normal antifungal susceptibility.
We used site-directed mutagenesis and mutated a subset of these conserved amino acids
(L13A, Y17A, Y37A, E39D, I47A, L51A, and N63Q) (Fig 1A; asterisk). We also mutated the
conserved cysteine residues Cys3 and Cys6, and Cys27 and Cys30 that are found within the
zinc-binding domain to alanines (Fig 1A; asterisk). We ectopically expressed individual full-
length Arv1-HA mutants in Scarv1 cells using a low copy centromeric plasmid, and subse-
quently determined their growth in the presence of antifungal drugs.
Arv1 mutant protein levels are shown in Fig 2C. A number of strains had reduced detect-
able levels of Arv1 protein (Fig 2C & 2D). However, while a number of these mutants were
expressed at low levels, they were still able to confer normal antifungal susceptibility to Scarv1
cells (see below).
We found that Scarv1 cells expressing the ScArv1L13A, ScArv1C27A, ScArv1I47A, or
ScArv1N63Q mutants were hypersusceptible to itraconazole, fluconazole, terbinafine, fenpropi-
morph, but had normal susceptibility to lovastatin (Table 1). Scarv1 cells expressing all other
ScArv1 mutants had normal susceptibility to all antifungal drugs tested (ScArv1C3A,
ScArv1C6A, ScArv1Y17A, ScArv1C30A, ScArv1Y37A, ScArv1E39D, and ScArv1L51A).
Further examination of the protein levels and the azole hypersusceptibility of various
mutants revealed that Scarv1 cells expressing ScArv1C27A remained azole hypersusceptible, but
had a protein level that was similar to that detected for ScArv1Y37A, whose expression was able
to confer normal azole susceptibility. Moreover, while ScArv1Y17A and ScArv1YI47A were
expressed to similar levels, only cells expressing ScArv1Y17A showed normal susceptibility.
Thus, there does not seem to be a direct correlation between reduced detectable ScArv1 pro-
tein and azole hypersusceptibility.
Possible explanations for these results may be that lower expressing mutants, which retain
activity, localize to a membrane fraction that is resistant to extraction, or may be more tightly
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Fig 2. The expression of specific ScArv1 mutants result in reduced protein levels. Cells were grown to exponential
phase (0.3–0.5 X 107 cells/ml) and used to obtain a total cell lysate. Western analysis was used to determine the size and
protein levels of ScARV1-HA mutants (anti-HA monoclonal antibody (clone 12CA5). ScPgk1 level was used as a
loading control. (A) Protein levels of Arv1 truncations. (B) Relative protein expression of truncations. (C) Protein
levels of ScArv1 point mutants. (D) Relative protein expression of point mutants. The westerns presented and
densitometry values are representative of 5 individual experiments. Relative protein expression was determined using
the densitometry values obtained for Arv1-HA proteins (numerator) compared to the ScPgk1 loading control
(denominator). �p�0.01; ���p�0.001; ���p�0.0001.
https://doi.org/10.1371/journal.pone.0235746.g002
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associated with the endoplasmic reticulum, again making it difficult to extract. We did not
examine if any protein was associated with detergent resistant membranes/rafts [32], or were
more tightly retained in the ER [26, 28].
Scarv1 cells expressing the ScArv1C27A mutant have altered sterol composition
We previously showed that Scarv1 cells accumulated lanosterol and unknown sterol interme-
diates, suggesting a role for ScArv1 in sterol synthesis [26]. Based on these results, we deter-
mined the sterol compositions for a subset of mutants using gas chromatography/mass
spectrometry. We chose the mutants to be analyzed based on whether they did or did not sup-
press azole hypersusceptibility, and protein expression levels. ScArv1C3A and ScArv1Y37A were
chosen as mutants able to restore normal antifungal susceptibility to Scarv1 cells, while
ScArv1C27A was chosen as an antifungal hypersusceptible mutant.
We found that Scarv1 cells expressing Arv1 had a normal sterol composition, whereas the
sterol composition was altered in Scarv1 cells expressing the ScAhd or ScΔAhd truncations.
These cells accumulated lanosterol (�) and unknown sterol intermediates (#) (Fig 3A) [26].
Moreover, Scarv1 cells expressing ScArv1C27A or ScArv1Y37A also accumulated lanosterol and
unknown sterol intermediates (Fig 3A).
Scarv1 cells expressing ScArv1C27A have altered sterol localization
Our studies [23, 25], as well as those from the Beh and Mennon laboratories [28], showed that
Scarv1 cells were unable to properly localize sterols. Thus, we visualized sterol localization in
Scarv1 cells expressing mutant proteins using filipin staining. Sterol localization was visualized
by fluorescence microscopy. 300–500 cells were analyzed, and the percentages of specific sterol
structures were determined.
Table 1. Antifungal susceptibilities of Scarv1 site-directed mutant strains.
Strain Itraconazole Fluconazole Terbinafine Fenpropimorph Lovastatin
W303a (WT) 0.24 ± 0.03 0.47 ± 0.02 6.9 ± 0.38 4.3 ± 0.83 39 ± 2.6
arv1 0.01 ± 0.01�� 0.12 ± 0.03�� 0.38 ± 0.04��� 0.72 ± 0.13��� 31 ± 1.3
arv1 + ARV1 0.25 ± 0.06 0.48 ± 0.04 9.6 ± 1.2 5.7 ± 0.89 43 ± 1.5
arv1 + Ahd 0.09 ± 0.03�� 0.08 ± 0.04�� 0.14± 0.05��� 1.1 ± 0.08��� 41 ± 2.3
arv1 + ΔAhd 0.13 ± 0.05�� 0.07 ± 0.03�� 1.6 ± 0.6��� 1.5 ± 0.21��� 36 ± 2.4
arv1 + ARV1C3A 0.26 ± 0.03 0.60 ± 0.05 5.8 ± 0.8 6.1 ± 1.3 51 ± 3.7
arv1 + ARV1C6A 0.33 ± 0.08 0.62 ± 0.05 7.9 ± 2.7 3.9 ± 0.66 33 ± 2.5
arv1 + ARV1L13A 0.02 ± 0.00�� 0.13 ± 0.02��� 0.76± 0.33��� 0.15 ± 0.03��� 27 ± 3.8
arv1 + ARV1Y17A 0.17 ± 0.04 0.53 ± 0.03 7.3 ± 0.41 5.5 ± 0.42 29 ± 1.4
arv1 + ARV1C27A 0.06 ± 0.03�� 0.15 ± 0.03�� 1.8 ± 0.24��� 0.95 ± 0.01��� 36 ± 1.7
arv1 + ARV1C30A 0.25 ± 0.02 0.63 ± 0.07 6.4 ± 1.4 4.8 ± 1.1 44 ± 3.6
arv1 + ARV1Y37A 0.19 ± 0.01 0.58 ± 0.04 8.4 ± 2.1 6.1 ± 0.26 36 ± 2.4
arv1 + ARV1E39D 0.17 ± 0.04 0.44 ± 0.03 6.1 ± 0.34 4.4 ± 0.81 41 ± 4.1
arv1 + ARV1I47A 0.05 ± 0.04� 0.09 ± 0.01�� 0.49 ± 0.19��� 1.4 ± 0.04��� 46 ± 6.2
arv1 + ARV1L51A 0.21 ± 0.04 0.72 ± 0.07 6.7 ± 0.71 3.9 ± 0.12 48 ± 3.7
arv1 + ARV1N63Q 0.10 ± 0.02�� 0.41 ± 0.01�� 0.84 ± 0.03��� 3.1 ± 0.03��� 51 ± 7.6
avalues are μg/ml.
b�P<0.01
��P<0.001
���P<0.0001.
https://doi.org/10.1371/journal.pone.0235746.t001
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We found that exponentially growing Scarv1 cells expressing ScArv1 had the majority of
their sterol localized to the plasma membrane rim (Fig 3B. RIM; ARV1), while Scarv1 cells con-
tained several aberrant types of sterol-containing structures, including membrane strands,
which may be sterol-accumulating organelle membranes, and punctate structures that are
mainly associated with the plasma membrane [28]. These structures were still seen at stationary
phase of growth, suggesting that there was not a slower sterol localization defect in these cells.
While Scarv1 cells expressing ScArv1C3A also showed rim staining, Scarv1 cells expressing
ScArv1C27A or ScArv1Y37A harbored sterol localization defects that were similar to those seen
for Scarv1 cells (Fig 3B). These cells accumulated both intercellular membrane strands and
plasma membrane-associated punctate structures to high degrees (Fig 3B).
Erg11 protein levels are reduced in Scarv1 cells expressing ScArv1C27A
ScErg11 is the direct target of azoles. We previously showed a direct correlation between azole
hypersusceptibility and reduced steady-state levels of ScErg11 in Scarv1 cells [25]. Normal
Fig 3. Scarv1 expressing ScArv1C27A and ScArv1Y37A are unable to maintain proper sterol composition and
localization. (A) Sterol composition and localization was determined in Scarv1 cells expressing ScArv1 mutants. Sterol
composition was determined by LC/MS as described in Materials and Methods. Sterol levels were plotted as a
percentage of total cellular sterol content. Data represent the percentages of lanosterol (black bars) and unknown sterol
intermediates (white bars). (B) The localization of unesterified sterol was visualized using filipin staining and
fluorescence microscopy. Values are the percentage of cells with the indicated structures. The data are representative of
5 individual double-blinded experiments. 300–500 cells were analyzed for each individual experiment. �p�0.01;
��p�0.001; ���p�0.0001; ## p�0.01; ## p�0.001; ### p�0.0001.
https://doi.org/10.1371/journal.pone.0235746.g003
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ScErg11 levels could be restored to Scarv1 cells if ScArv1 or CaArv1 was expressed [25], again
demonstrating a high degree of conservation. To further delve into the mechanism(s) respon-
sible for the azole hypersusceptibility and sterol defects of Scarv1 cells, we determined ScErg11
levels in Scarv1 cells expressing mutant proteins.
Wild type levels of ScErg11-MYC were seen in Scarv1 cells expressing full-length ScArv1,
whereas levels were reduced in Scarv1 cells, and Scarv1 cells expressing ScAhd or ScΔAhd
alone (Fig 4A & 4B). Scarv1 cells expressing ScArv1C3A, ScArv1C27A or ScArv1Y37A also had
reduced levels of ScErg11-MYC.
Erg11 instability in Scarv1 cells expressing ScArv1C27A is due to accelerated
protein degradation
We wanted to understand what mechanism was responsible for reducing the steady state level
of Erg11. We first determined whether ScERG11 mRNA was unstable. The ½ life of ScERG11
mRNA was compared to the ½ life of ScPGK1 mRNA. We found no differences in mRNA sta-
bility between ScERG11 (open circles) and ScPGK1 (closed circles) (Fig 4C). Similar results were
seen in Scarv1 cells expressing Ahd, ΔAhd, ScArv1C3A, ScArv1C27A, or ScArv1Y37A (not
shown). Thus, the reduced ScErg11-MYC protein level seen in Scarv1 cells expressing
Scarv1C27A was not due to the accelerated decay of ScERG11 mRNA.
We next analyzed whether Erg11 was being degraded faster. Thus, we determined its ½ life
in Scarv1 cells. We did this by following the synthesis and degradation of a ScErg11-MYC pro-
tein, whose expression was under the control of the inducible GAL1 promoter. Cells were
grown in 2% raffinose to exponential phase and shifted to galactose for 2 hr to induce protein
expression. After 2hr, glucose was added to shut off galactose-inducible protein expression,
and ScErg11 levels were determined at the indicated times post glucose addition using western
analysis. Cyclohexamide (CHX) was added during glucose addition in order to inhibit protein
translation.
We found that ScErg11 ½ life was ~45 min in Scarv1 cells expressing ScArv1, while it was
~15 min in Scarv1 cells (Fig 4D & 4E). The densitometry units shown in Fig 4E are representa-
tive of the levels of ScErg11-MYC in Fig 4D.
We next examined if the reduced ½ life of ScErg11 in Scarv1 cells was due to accelerated
proteosomal degradation. We chose to look at ScErg11 levels at 45 min, the ½ life of ScErg11-
MYC in ScARV1 cells, as this time point gave us the most consistent results. Pulse-chase exper-
iments were again used, and cells were grown in the absence or presence of the proteosome
inhibitor, MG132.
The addition of MG132 to Scarv1 cells expressing ScArv1 stabilized ScErg11-MYC when
compared to cells grown in the absence of MG132 (Fig 5A; CHX vs. CHX +MG132). MG132
addition also stabilized ScErg11-MYC in Scarv1 cells, albeit not to the same level observed for
Scarv1 cells expressing ScArv1 (Fig 5A; Arv1 vs. arv1, CHX vs. CHX +MG132). While Scarv1
cells expressing ScArv1C3A, ScArv1C27A, or ScArv1Y37A, had lower levels of Erg11-MYC in the
absence of MG132 (Fig 5A; CHX), protein levels became stable in these cells in the presence of
MG132 (Fig 5A; CHX vs. CHX +MG132). These results suggested that accelerated proteosome
degradation might play a role in causing Erg11-MYC instability in Scarv1 cells expressing
ScArv1C27A. The densitometry units shown in Fig 5B are representative of the levels of
ScErg11-MYC in Fig 5A.
To determine if accelerated proteosome degradation was solely responsible for Erg11-MYC
instability, we analyzed Erg11-MYC levels in Scarv1 cells lacking proteosome chymotrypsin-
like activity (pre1-1 pre2-2), deubiquitination recycling activity (doa4), or carboxypeptidase
activity (pep4). Interestingly, Erg11-MYC steady state levels were stable in Scarv1 cells lacking
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Fig 4. Scarv1 expressing ScArv1C27A and ScArv1Y37A are unable to maintain normal steady-state levels of ScErg11.
Whole cell lysates from Scarv1 cells expressing ScArv1 mutants were resolved by SDS-PAGE and transferred to
nitrocellulose. ScErg11-MYC levels were determined by western analysis using an anti-MYC monoclonal antibody
(9E10). ScPgk1 was used as a loading control. (A) ScErg11-MYC levels in Scarv1 cells expressing Arv1 mutants. (B)
Relative protein expression of ScErg11-MYC compared to ScPgk1. Relative protein expression was determined using
the densitometry values obtained for ScErg11-MYC protein (numerator) compared to the ScPgk1 loading control
(denominator). The data shown are representative of 5 individual experiments. (C) ScERG11 and ScPKG1 mRNA
expression levels. Thiolutin, which is an inhibitor of bacterial and yeast RNA polymerases, was used at 3μg/ml. The
data presented are representative of 5 individual experiments. WT, closed circles; arv1, open circles. (D) The half-life of
ScErg11-MYC was determined by pulse-chase kinetic experiments where expression was driven from the GAL1
promoter and initiated by addition of galactose. The indicated times are post addition of glucose, which stops GAL1-
driven protein expression. Protein lysates were obtained and protein level was determined using western analysis and
an anti-MYC monoclonal antibody (9E10). (E) Relative densitometry units are representative of the data shown in
panel D. WT, black bars; arv1, white bars. The data are representative of 5 individual experiments. ��p�0.001;
���p�0.0001.
https://doi.org/10.1371/journal.pone.0235746.g004
Fig 5. ScErg11 protein level is stabilized in Scarv1 cells expressing ScArv1C27A in the presence of the proteosome
inhibitor, MG132. Cells were treated with cyclohexamide (translation inhibitor) in the absence or presence of MG132
(proteosome inhibitor) for 45 min. ScErg1/6/11/24/25-MYC levels were determined by western analysis using an anti-
MYC monoclonal antibody (9E10). ScPgk1 was used as a loading control. (A) ScErg11 levels were determined in
cyclohexamide-treated Scarv1 cells expressing Arv1 mutants in the absence and presence of MG132 for 45 min. (B)
Relative densitometry units are representative of the data shown in panel A. (C) ScErg11 levels were determined in
cells lacking proteosomal chymotrypsin-like activity (pre1 pre2), ubiquitin-dependent degradation (doa4), or
carboxypeptidase activity (pep4). (D) Relative densitometry units are representative of the data shown in panel C. (E)
ScErg1/6/24/25-MYC levels were determined in cyclohexamide-treated Scarv1 cells in the absence and presence of
MG132 for 45 min. (F) Relative densitometry units are representative of the data shown in panel E.
https://doi.org/10.1371/journal.pone.0235746.g005
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Pre1/Pre2 or Doa4 activity, but remained unstable in cells lacking Pep4, when compared to
Scarv1 cells (Fig 5C). The densitometry units shown in Fig 5C are representative of the levels
of ScErg11-MYC in Fig 5B.
Finally, we determined whether the stability of additional Erg proteins was dependent on
the presence of Arv1. We generated Scarv1 cells expressing ScErg1-MYC, ScErg6-MYC,
ScErg24-MYC, or ScErg25-MYC, and tested protein stability in the absence or presence of
MG132 at 45 min. Both ScErg1-MYC and ScErg25-MYC were expressed at low levels in
Scarv1 cells, but protein levels became stable in the presence of MG132 (Fig 5E; CHX vs. CHX
+MG132). Interestingly, both ScErg6-MYC and ScErg24-MYC were expressed at the same
level either in the absence or presence of MG132 (Fig 5E; CHX vs. CHX +MG132). The densi-
tometry units shown in Fig 5F are representative of the levels of ScErg1-MYC, ScErg6-MYC,
ScErg24-MYC, and ScErg25-MYC in Fig 5E. Thus, the presence of ScArv1 seems to be neces-
sary for maintaining the stability of a subset of enzymes required for ergosterol biosynthesis.
Erg11 physically interacts with Arv1
Johnsson and Varshavsky [33] first described the split-ubiquitin two-hybrid system for looking
at the interactions between membrane-bound proteins. This method takes advantage of the N-
terminal (Nub) and C-terminal (Cub) halves of ubiquitin to detect protein-protein interac-
tions. The Nub and Cub protein fragments are fused to bait and prey proteins, respectively.
The Cub protein itself is a chimera that contains a transcription factor (protein-A-LexA-VP16)
that is released upon protein-protein binding, whereby it can activate reporter gene expres-
sion. Expression of the HIS3 gene allows for growth in the absence of histidine and β-galactosi-
dase activity from the LacZ gene.
Bard and colleagues previously demonstrated that ScArv1 physically interacted with
ScErg11 using the split-ubiquitin two-hybrid system [6]. They also demonstrated several ScErg
protein-protein interactions that were necessary for sterol synthesis [34]. Moreover, they
found that the level of the C-24 sterol methyltransferase Erg6 was decreased in erg28 cells.
Erg28 acts as a scaffold, nucleating the ergosome that is responsible for sterol biosynthesis
[35]. Based on these results, we tested whether ScErg11 stability was dependent on its ability to
interact with ScArv1, and ScArv1 truncations or mutants. Positive and negative controls were
designed based on the strong interaction between ScErg28 and Erg27, and the lack of interac-
tion between ScErg28 and ScErg9, respectively [6].
As previously reported, we detected an interaction between ScErg28 and ScErg27, as these
cells grew in the absence of tryptophan, leucine, and histidine (Trp- Leu- His-), and had a
15-fold increase in β-galactosidase activity over that observed for the negative interaction con-
trol (ScErg28-Cub X ScErg9-NubG) (Fig 6A).
We next looked for an interaction between ScErg11 and full-length or truncated forms of
ScArv1. We observed an interaction for ScErg11 and full-length ScArv1, but not between
ScErg11 and the ScAhd or ScΔAhd fragments (Fig 6B). Interestingly, we also observed an
interaction between ScErg11 and ScArv1C3A and ScArv1Y37A, but not with ScArv1C27A (Fig
6B). We next decided to examine whether these same interactions were conserved in C. albi-
cans. We obtained the same results. CaErg11 interacted with full-length CaArv1, CaArv1C3A,
and CaArv1Y38A, but did not interact with CaAhd, CaΔAhd, or CaArv1C28A (Fig 6C).
Next, we determined if we could recapitulate our two-hybrid results using co-immunopre-
cipitation experiments. The top panels of Fig 7A–7D (cell lysate) are westerns showing the
total amount of each protein in cell lysates. The bottom panels of Fig 7A–7D are the co-immu-
noprecipitation results using western analysis (immunoblot).
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We first examined whether ScErg11-MYC and ScArv1-HA could co-immunoprecipitate in
Scarv1 cells. We were able to pull down ScErg11-MYC with ScArv1-HA using either anti-
MYC or anti-HA monoclonal antibodies (Fig 7A, immunoblot). We next co-expressed
ScArv1C3A-HA, ScArv1C27A-HA, or ScArv1Y37A-HA, with ScErg11-MYC, and performed co-
immunoprecipitation experiments. Scarv1 cells expressing ScArv1C3A-HA had detectable lev-
els of ScArv1C3A-HA and ScErg11-MYC (Fig 7A vs. 7B; cell lysate). We were able to co-immu-
noprecipitate ScErg11-MYC and ScArv1C3A-HA in these cells (immunoblot).
Scarv1 cells expressing Arv1C27A-HA or ScArv1Y37A-HA had reduced levels of ScArv1-HA
and ScErg11-MYC (Fig 7C vs. 7A; cell lysate). Importantly, we found that we were able to co-
immunoprecipitate ScArv1Y37A-HA and ScErg11-MYC in Scarv1 cells (Fig 7C, immunoblot),
but were not able to co-immunoprecipitate ScArv1C27A-HA and ScErg11-MYC (Fig 7D,
immunoblot).
CaArv1 interacts with CaErg11 in Scarv1 cells
We next tested if the physical interaction between ScArv1-HA and ScErg11-MYC was con-
served in C. albicans. Here we expressed CaArv1C3A, and conserved CaArv1C28A and CaAr-
v1Y38A, in Scarv1 cells expressing CaErg11-MYC. We observed the same co-
immunoprecipitation results that we saw with the S. cerevisiae proteins. Scarv1 cells expressing
CaArv1-HA or CaArv1C3A-HA had normal levels of protein (Fig 8A & 8B, cell lysate), and
each mutant was able to co-immunoprecipitate with CaErg11-MYC (Fig 8A & 8B). Scarv1
Fig 6. Both ScArv1C27A and CaArv1C28A are unable to interact with ScErg11 and CaErg11, respectively, using the
split-Ub two-hybrid system. Cells expressing chimeric forms of ScArv1/CaArv1 were grown to exponential phase in
the appropriate plasmid selection medium. Serial dilutions of cells were dropped onto plates using a pin tool, and cell
growth was visualized after 48 hr. True protein-protein interactions were deemed true if cells grew on Trp-Leu-His-
agar plates, and had a>3-fold increase in β-galactosidase activity over baseline. (A) Growth rates of ScErg28-Cub X
ScErg9-NubG and ScErg28-Cub X ScErg27-NubG negative and positive interaction control cells, respectively. (B)
Growth rates of cells expressing mutant forms of ScArv1 and full-length ScErg11. (C) Growth rates of cells expressing
mutant forms of CaArv1 and full-length CaErg11. Data are representative of 5 individual experiments.
https://doi.org/10.1371/journal.pone.0235746.g006
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cells expressing CaArv1C28A-HA or CaArv1Y38A had reduced levels of CaArv1 protein (Fig 8C
& 8D, cell lysate). However, we found that CaArv1Y38A-HA was able to co-immunoprecipitate
with CaErg11-MYC, whereas CaArv1C28A-HA could not (Fig 8C vs. 8D, immunoblot).
Fig 7. ScArv1C27A does not co-immunoprecipitate with ScErg11. (A-D) Scarv1 cells co-expressing wild type and
mutant forms of ScArv1-HA and wild type ScErg11-MYC were grown to exponential phase in the appropriate drop
out medium for plasmid selection. Whole cell lysates were used for co-immunoprecipitation experiments. ScArv1-HA
and ScErg11-MYC levels were determined using western analysis using anti-HA monoclonal (12CA5) and
monoclonal anti-MYC (9E10) antibodies, respectively. Pgk1 was used as a loading control. (A-D, immunoblot),
represents the co-immunoprecipitation western results using the indicated anti-MYC antibodies or anti-HA
antibodies and indicated Arv1 mutants. The cell lysate panels represent Erg11-MYC or Arv1-HA levels in total cell
lysates. The difference in size of Erg11 in panel B may be due to post-translational modification. We have previously
found that Erg11 migrates as a higher molecular weight species in certain Arv1 mutants (not shown). The differences
in the detection observed for certain Arv1 mutants and Erg11 may be due to the use of protein lysates from steady state
cells, and is strain dependent. The panels represent data from 3 individual experiments.
https://doi.org/10.1371/journal.pone.0235746.g007
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CaArv1C28A does not interact with azole-resistant CaErg11Y132L F145L in
Scarv1 cells
Many azole resistant clinical isolates express CaERG11Y132L F145L, which harbors altered azole-
binding affinity (Fig 1B). We were interested in exploring whether CaArv1 had any role in sta-
bilizing this clinically relevant protein.
We performed co-immunoprecipitation experiments with Scarv1 cells co-expressing
CaArv1-HA, CaArv1C3A-HA, CaArv1C28A-HA, or CaArv1Y38A-HA, and CaErg11Y132L F145L-
MYC (Fig 9). We found that Scarv1 cells expressing CaArv1 or CaArv1C3A had similar levels
Fig 8. CaArv1C28A is unable to co-immunoprecipitate with ScErg11. Scarv1 cells co-expressing mutant CaArv1-HA
and wild type CaErg11-MYC were grown to exponential phase in the appropriate plasmid selection medium. (A-D),
represent the co-immunoprecipitation western results of Scarv1 cells co-expressing CaArv1 mutants and
CaErg11-MYC (immunoblot). The cell lysate panels represent Erg11-MYC or Arv1-HA protein levels in total cell
lysates. The differences in the detection observed for certain Arv1 mutants and Erg11 may be due to the use of protein
lysates from steady state cells, and is strain dependent. The panels represent data from 3 individual experiments.
https://doi.org/10.1371/journal.pone.0235746.g008
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of CaArv1 and CaErg11Y132L F145L-MYC (Fig 9A & 9B; cell lysate), whereas, Scarv1 cells
expressing CaArv1C28A-HA or CaArv1Y38A-HA had reduced levels of CaArv1 and CaEr-
g11Y132L F145L-MYC (Fig 9C & 9D, cell lysate). CaArv1-HA, CaArv1C3A-HA, and CaArv1Y38A
were able to co-immunoprecipitate with CaErg11Y132L F145L-MYC (Fig 9A, 9B & 9D, immuno-
blot). However, CaArv1C28A lacked this ability (Fig 9C, immunoblot).
The possibility does exist that the lack of interaction we see between ScArv1C27A-HA and
CaArv1C28A-HA, and ScErg11-MYC and CaErg11-MYC, respectively, may be due merely to
low levels of protein, rather than a loss of a protein-protein interaction. We do not believe this
is the case because the expression of CaArv1Y37A-HA and CaArv1Y38A-HA are similar to
ScArv1C27A-HA and CaArv1C28A-HA, respectively, yet only CaArv1Y37A-HA and CaArv1Y38A-
HA interact with ScErg11-MYC and CaErg11-MYC, respectively. We point out that Erg11
Fig 9. CaArv1C28A is unable to co-immunoprecipitate with CaErg11Y132L F145L. Scarv1 cells co-expressing
CaArv1-HA mutants and wild type CaErg11Y132L F145L-MYC were grown to exponential phase in the appropriate
plasmid selection medium. (A-D), represents the co-immunoprecipitation western results using the indicated anti-
MYC antibodies or anti-HA antibodies and indicated Arv1 mutants (immunoblot). The cell lysate panels represent the
total Erg11-MYC or Arv1-HA protein levels in total cell lysates. The panels represent data from 3 individual
experiments. The differences in detection seen are due to the use of protein lysates from steady state cells. The panels
represent data from 3 individual experiments.
https://doi.org/10.1371/journal.pone.0235746.g009
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displayed different migration patterns using western analysis. We believe this may due to post-
translational modification, such as phosphorylation. We cannot rule this out at this time.
Scarv1 cells expressing ScArv1C27A accumulate aberrant ER membrane
structures
To further explore what was the reason for the loss of physical interaction between Arv1 and
Erg11, we determined if there was a link between defects in ER morphology and loss of pro-
tein-protein interaction. We visualized the subcellular localization pattern of the ER resident
Rtn2-GFP protein using fluorescence microscopy [36], and based on its subcellular localiza-
tion pattern, we determined whether cells accumulated cytosolic ER membranes and/or
formed ER aggregate structures (Fig 10).
Scarv1 cells expressing ScArv1 accumulated ~12% cytosolic ER membranes (Fig 10A vs.
10B; normal vs. ER membranes). Scarv1 cells expressing ScArv1C3A had similar levels, whereas,
Scarv1 cells, and Scarv1 cells expressing ScArv1C27A or ScArv1Y37A, hyper-accumulated these
structures (Fig 10A vs. 10B; normal vs. ER membranes). Peripheral ER aggregates only accumu-
lated in Scarv1 cells to any substantial degree (Fig 10C vs. 10D; normal vs. peripheral ER aggre-
gates. The densitometry units shown in panels 10E and 10F are representative of the
percentage of ER membranes and peripheral ER aggregates observed in panels 10B and 10D.
ScErg11 is mislocalized in Scarv1 cells expressing ScArv1C27A
We next wanted to see if there was a correlation between the defects in ER morphology and
the mislocalization of ScErg11. To circumvent the possible reduced protein level of
ScErg11-GFP in cells expressing ScArv1C27A/CaArv1C28A and ScArv1Y37A/CaArv1Y38A, which
Fig 10. Scarv1 cells expressing ScArv1C27A accumulates cytosolic ER membrane structures. S. cerevisiae cells were
grown in the appropriate plasmid selection medium. Cells were transformed with YCplac111-RTN2-GFP (RTN2 under
its own promoter in CEN/ARS LEU2 vector). For microscopy studies, cells were diluted to approximately OD600nm
0.15. Cells were imaged using a Zeiss AxioImager.Z2 epifluorescence upright microscope with a 100X Plan-
Apochromatic 1.4 numerical aperture objective lens. An increase in ER membrane fluorescence at medial (B) or
cortical optical sections (D) were manually detected as described in Materials and Methods. (E) Percentage of cells
displaying cytosolic ER membranes. (F) Percentage of cells displaying peripheral ER aggregates. 300–500 cells were
counted in 3 individual experiments. Arrows in panels B & D point out cytosolic ER membranes and peripheral ER
aggregates, respectively. White bar represents 10 um. �p� 0.01; ��p� 0.001; ���p� 0.0001.
https://doi.org/10.1371/journal.pone.0235746.g010
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may not allow us to visualize localization, ScErg11 expression was driven by the highly active
GPD (glyceraldehyde-3-phosphate dehydrogenase) promoter.
We found that ScErg11-GFP localized to the ER in Scarv1 cells expressing ScArv1,
ScArv1C3A or ScArv1Y37A, whereas it was mislocalized in Scarv1 cells and Scarv1 cells express-
ing ScArv1C27A (Fig 11; asterisk). Similar results were seen in Caarv1/Caarv1 cells expressing
CaErg11-GFP. We saw proper localization of GFP-CaErg11 in Caarv1/Caarv1 cells expressing
CaArv1C3A or CaArv1Y38A, while it was mislocalized in cells expressing CaArv1C28A (Fig 11;
asterisk).
Scarv1 cells expressing ScArv1C28A show constitutive activation of the
unfolded protein response
The unfolded protein response (UPR) is constitutively activated is Scarv1 cells [29]. The reason
for this phenotype is unknown, but may be due to accumulation of lipids in the ER. As Scarv1
cells accumulate lanosterol and unknown sterol intermediates, we asked whether a correlation
existed between activation of the UPR and mislocalization of ScErg11. UPR signaling was ana-
lyzed by assaying for β-galactosidase activity driven by an integrated unfolded protein response
promoter element (UPRE-LacZ).
We found a direct correlation between the mislocalization of GFP-ScErg11 and an activated
UPR (Fig 12A). The UPR was constitutively activated in Scarv1 and Scarv1 cells expressing
ScArv1C27A, whereas it remained at basal levels in Scarv1 cells expressing ScArv1, ScArv1C3A,
or ScArv1Y37A (Fig 12A).
We further explored the level of UPR signaling in Caarv1/Caarv1 cells expressing various
mutants. Here, we assayed for the level of CaHAC1 (homologous to ATF/CREB1) mRNA
splicing [39]. HAC1 mRNA is spliced from 581 bp to 562 bp when the UPR becomes activated.
Tunicamycin treatment of CaARV1/CaARV1 cells, which activates the UPR, resulted in
Fig 11. ScArv1 and CaArv1 are required for proper ER localization of GFP-Erg11. GFP-ScErg11 and GFP-CaErg11
proteins, each driven from the ScGPD promoter, were expressed in Scarv1 and Caarv1/Caarv1 cells, respectively. Cells
were grown to exponential phase and GFP-Erg11 was visualized by fluorescence microscopy using a Leica RBME
fluorescence microscope and 100X optics. 300–500 cells were counted for each strain using double-blind analysis in 5
individual experiments. The values represent the percentage of cells containing the designated structures. The ER
localization of Erg11 has been reported previously [37]. Asterisk indicates cells that display defects in GFP-Erg11
localization.
https://doi.org/10.1371/journal.pone.0235746.g011
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substantial CaHAC1 mRNA splicing, indicating that CaARV1/CaARV1 cells can properly
respond upon being stressed (Fig 12B; tunicamycin). Under basal conditions in the absence of
stress, we did not observe CaHAC1 mRNA splicing in Caarv1/Caarv1 cells expressing CaArv1,
CaArv1C3A, or CaArv1Y38A. On the other hand, Caarv1/Caarv1 and cells expressing
CaArv1C28A had a significant increase in the accumulation of the 562 bp spliced HAC1
mRNA, indicating that the UPR was constitutively activated (Fig 12B). The degree of splicing
in these cells was similar to that for CaARV1/CaARV1 cells treated with tunicamycin (Fig 12B;
tunicamycin).
Fig 12. Expression of ScArv1C27A and CaArv1C28A activates the unfolded protein response in Scarv1 and Caarv1/
Caarv1 cells, respectively. (A) Scarv1 strains expressing the integrated UPRE-LacZ reporter were grown to
exponential phase in the appropriate medium. Cells were assayed for the degree of unfolded protein response
activation (UPR) by determining β-galactosidase activity. β-galactosidase activity was assayed as described in Materials
and Methods. β-galactosidase units were calculated using a previously published equation [38]. (B) The unfolded
protein response was determined in Caarv1/Caarv1 cells by examining the level of HAC1 mRNA splicing using
HAC1-5RT (TGAGGATGAACACCAAGAAGAA) and HAC1-3RT (TCAAAGTCCAACTGAAATGAT) primers and
RT-PCR [39]. The levels of unfolded protein activation in various strains were compared to CaARV1/CaARV1 cells
treated with 2μg/ml tunicamycin for 2 hr to activate the UPR (tunicamycin). Tunicamycin is an antibiotic that is
commonly used to activate ER stress and the UPR. The β-galactosidase results shown in panel A are the average of 5
individual experiments. The agarose gel in panel B is a representative of the results of 5 independent experiments ��p�
0.001; ���p� 0.0001.
https://doi.org/10.1371/journal.pone.0235746.g012
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Carv1/Caarv1 cells expressing CaArv1C28A are hypersusceptible to azole
antifungal drugs
To determine if the loss of a CaErg11-CaArv1 interaction in C. albicans cells affects azole sus-
ceptibility, we grew Caarv1/Caarv1 cells expressing CaArv1C3A, CaArv1C28A, or CaArv1Y38A,
in the presence of itraconazole or fluconazole, and we determined MIC concentrations. We
found that Caarv1/Caarv1 cells were hypersusceptible to both antifungal drugs (Table 2).
Caarv1/Caarv1 cells expressing CaArv1C28A were also hypersusceptible to either antifungal
(Table 2), while cells expressing CaArv1C3A or CaArv1Y38A retained normal susceptibility.
Interestingly, expressing Erg11Y132L Y145L in Caarv1/Caarv1 cells expressing CaArv1C28A did
not restore normal susceptibility to itraconazole or fluconazole. Nor did it result in resistance
when co-expressed in Caarv1/Caarv1 cells expressing CaArv1C3A or CaArv1Y38A.
Caarv1/CaArv1 cells co-expressing CaArv1C28A and CaErg11Y132L F145L lack
virulence
Finally, we determined whether the loss of interaction between CaArv1C28A and CaErg11 cor-
related with a lack of virulence in a disseminated candidiasis murine model. We constructed
Caarv1/Caarv1 strains expressing CaArv1, CaArv1C3A, CaArv1C28A, CaArv1Y38A, or strains
co-expressing CaErg11Y132L F145L with CaArv1C3A, CaErg11Y132L F145L, or CaArv1C28A. We
injected BALB/C mice with each strain and monitored survival for 30 days.
We found that mice injected with CaARV1/CaARV1, Caarv1/CaARV1, Caarv1/
CaARV1C3A, and Caarv1/ARV1Y38A cells all died within 6 days (Fig 13). In contrast, mice
injected with Caarv1/Caarv1 or Caarv1/CaARV1C28A cells remained viable for the entire time
of the study. Interestingly, we found that mice injected with Caarv1/Caarv1 cells expressing
CaErg11Y132L F145L also remained viable for the entire study, suggesting that CaErg11Y132L
F145L expression was unable to eliminate the deleterious effect of losing CaArv1. Finally, we
observed that Caarv1/Caarv1 cells co-expressing CaArv1C28A and CaErg11Y132L F145L also
lacked virulence, while Caarv1/Caarv1 cells expressing CaArv1Y38A and CaErg11Y132L F145L
retained virulence.
Discussion
Fungal infections caused by azole resistant Candida spp. are a major health concern for the
immune compromised. Azole-resistant Candida spp. are emerging in the clinic. Here, we
Table 2. Antifungal susceptibilities of Caarv1/Caarv1 mutant strains.
Strain Itraconazole Fluconazole
BWP17 (WT) 0.44 ± 0.13 12.5 ± 2.6
Caarv1/Caarv1 0.08 ± 0.01�� 1.4 ± 0.3��
Caarv1/Caarv1 + CaARV1 0.57 ± 0.17 16 ± 3.1
Caarv1/Caarv1 + CaARV1C3A 0.49 ± 0.03 11.3 ± 0.25
CaArv1/Caarv1 + CaARV1C28A 0.02 ± 0.07��� 0.94 ± 0.05���
Caarv1/Caarv1 + CaARV1Y38A 0.53 ± 0.07 14.8 ± 1.6
Caarv1/Caarv1 + CaARV1C3A Y132L Y145L 0.64 ± 0.26 10.90 ± 2.4
CaArv1/Caarv1 + CaARV1C28A Y132L Y145L 0.04 ± 0.03��� 3.7 ± .086���
Caarv1/Caarv 1 + CaARV1Y38A Y132L Y145L 0.71 ± 0.11 15.8 ± 1.03
avalues are μg/ml.
���p<0.0001.
https://doi.org/10.1371/journal.pone.0235746.t002
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uncovered that Cys27 within the ScAhd is required for normal azole susceptibility, proper ste-
rol synthesis, and ScErg11 stability, all of which require that ScArv1 and ScErg11 interact and
form a complex. Scarv1 cells expressing ScArv1C27A were azole hypersusceptible, harbored
reduced levels of ScErg11, and accumulated the Erg11 substrate, lanosterol. In addition,
ScArv1C27A was unable to co-immunoprecipitate with ScErg11. Scarv1 cells expressing
CaArv1C28A displayed the same phenotypes. Importantly, Caarv1/Caarv1 cells expressing
CaArv1C28A lacked virulence, and expressing CaErg11Y132L Y145L in these cells was unable to
restore virulence in a mouse model of candidiasis. These results strongly suggest that one func-
tion of Arv1 is to interact with and stabilize Erg11. This interaction may be required for the
virulence of C. albicans cells.
Fig 13. Caarv1/Caarv1 cells expressing CaArv1C28A lack virulence. BALB/C mice were tail vein injected with
Caarv1/Caarv1 cells expressing CaArv1C3A, CaArv1C28A, CaArv1Y38A, or Caarv1/Caarv1 cells co-expressing
CaArv1C3A and Erg11Y132L F145L, CaArv1C28A and Erg11Y132L F145L, or CaArv1Y38A and Erg11Y132L F145L. Viability was
examined daily for 30 days. Mice injected with Caarv1/Caarv1 expressing CaArv1C28A remained viable during the
entire time of the study, whereas mice injected with Caarv1/Caarv1 expressing CaArv1Y38A died within a few days.
Mice injected with CaArv1C28A and Erg11Y132L F145L also died within a few days.
https://doi.org/10.1371/journal.pone.0235746.g013
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Initially, we focused our efforts on defining ScArv1 domains required for maintaining nor-
mal azole susceptibility and sterol synthesis. We found that neither the ScAhd nor ScΔAhd
could replace full-length ScArv1. As there is little to no homology between the ScΔAhd of
other Candida spp., we believe that ScΔAhd is only needed to tether the ScAhd to the ER
membrane.
We chose to focus on defining important conserved amino acids within the ScΔAhd that
were required for Arv1 function. While alanine substitution did cause reductions in protein
levels of certain ScArv1 mutants, we did not observe a direct correlation between loss of detect-
able protein level and hypersusceptibility to azole treatment (Fig 1; Table 1). In particular, our
results obtained using Scarv1 cells expressing ScArv1C27A and ScArv1Y37A. Both proteins were
expressed at low levels, but Scarv1 cells expressing ScArv1C27A remained hypersusceptible to
azoles, while Scarv1 cells expressing ScArv1Y37A showed a normal response.
Interestingly, Scarv1 cells expressing ScArv1C3A or ScArv1Y37A had defects in sterol compo-
sition and localization. However, Scarv1 cells expressing ScArv1Y37A had a normal UPR,
whereas Scarv1 cells expressing ScArv1C27A showed a constitutive activation. This suggests
that ScArv1Y37A expressing cells are able to retain some level of ER membrane integrity. This
may help to explain why ScArv1Y37A was able to interact with ScErg11, and that ScErg11 prop-
erly localized to the ER in Scarv1 cells expressing this protein. We found similar results for
Caarv1/Caarv1 cells expressing CaArv1C28A and CaArv1Y38A. Table 3 summarizes the pheno-
types of Scarv1 cells expressing ScArv1C27A or ScArv1Y37A.
Cys27 is found within the ScAhd zinc-binding domain, as is Cys28 in C. albicans. Both are
part of a cysteine cluster (two CXXC motifs separated by ~20 amino acids) that is conserved
across Candida spp. Many transcription factors have zinc-binding motifs that are involved in
DNA binding [40]. Moreover, this same motif has been shown to be required for protein-pro-
tein interactions [41, 42]. There is no evidence to date that suggests that Arv1 has any role in
directly regulating gene expression. It may however be needed for maintaining the stability
of certain Erg proteins, possibly through direct interaction. We found that ScArv1 was
required for ScErg1 and ScErg25 protein stability, but not ScErg6 or ScErg24. Based on these
data, our hypothesis is that the Ahd of ScArv1 may act as a scaffolding domain that is involved
in maintaining the stability of a subset of Erg proteins. Thus, it may function, along with the
ScErg28 scaffold, to stabilize the ergosome complex [43]. This function may be conserved in
C. albicans.
Table 3. Phenotypes of Arv1 proteins.
Phenotype ScArv1 Scarv1 ScArv1C27A ScArv1Y37A
Normal steady-state Arv1 protein level +++ - - -
Normal sterol composition +++ - - -
Normal sterol distribution +++ - - -
Normal steady-state Erg11 level +++ - - -
Erg11 stabilized by MG132 +++ ++ ++ ++
Positive interaction in Y2H +++ - - +++
Interacts with Erg11 +++ - - +++
Interacts with Erg11Y132L L145R +++ - - +++
Cytoplasmic ER membranes - +++ +++ ++
ER aggregates - +++ - -
Proper localization of Erg11 +++ - - +++
Activated UPR - +++ +++ -
virulence +++ - - +++
https://doi.org/10.1371/journal.pone.0235746.t003
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The addition of the proteosome inhibitor, MG132, stabilized ScErg11 in Scarv1 cells
expressing ScArv1C27A. ScErg11 was also stabilized in Scarv1 cells lacking the proteosomal
pre1/2 chymotrypsin-like enzymes, as well as cells lacking Doa4, which is involved in ubiquitin
recycling. Based on these data, our hypothesis is that the loss of Arv1 causes accelerated degra-
dation of ScErg11 through an ubiquitin-dependent mechanism, which ultimately targets it for
degradation by the proteosome. There is evidence other ScErg proteins are ubiquitinated.
Peng et al., [8] used a proteomic approach to identify ubiqutinated sites within the yeast prote-
ome. They found that ScErg11 was enriched in the ubiquitinated fraction and contained a
putative ubiquitination site. Other ScErg proteins that were enriched in this same fraction
included ScErg1/9/26/27. They also definitively confirmed the presence of multiple ubiquitina-
tion sites within ScErg3 and ScErg5. These results suggest that ubiquitin-dependent degrada-
tion of ScErg proteins may be a common mechanism used to maintain proper sterol
biosynthesis.
Based on our data, we have come up with a model for regulation of Erg11 stability and func-
tion (Fig 14). It is assumed that all arv1 mutants contain some level of Erg11, as erg11 null cells
are inviable. We believe that Arv1, through its interaction with Erg11, aids in retaining Erg11
in the ER, which is necessary for proper folding and function (Fig 14A). The absence of Arv1
results in the mislocalization of ScErg11, which leads to its accelerated degradation by the
Fig 14. Model depicting the role of Arv1 in maintaining Erg11 stability and virulence. (A) A direct physical interaction between Arv1 and Erg11 results in
stability of Erg11. This interaction may be required for maintaining Erg11 tertiary structure and/or tether it to the ER membrane. A stable Erg11-Arv1
complex confers virulence. (B) Erg11 becomes misfolded in the absence of Arv1, and may be targeted to the proteosome via ubiquitination. Cells lacking a
stable Erg11-Arv1 complex are azole hypersusceptible and lack virulence.
https://doi.org/10.1371/journal.pone.0235746.g014
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proteosome (Fig 14B). Degradation may or may not be driven by Erg11 polyubiquitination.
Erg11 degradation would presumably lead to accumulation of sterol in the ER, in particular,
lanosterol. Sterol accumulation may initiate or exasperate the degree of UPR activation. It is
presumed that multiple ER membrane-associated proteins would also be mislocalized by loss
of Arv1, thus it may not solely be the misfolding of ScErg11 that causes UPR activation. We
show here that ScErg1 and ScErg25 levels were reduced in Scarv1 cells, but were stabilized by
the addition of MG132. Overall, we suggest that the lack of virulence phenotype of Caarv1/
Caarv1 cells is partly due to severely reduced CaErg11 levels brought on by loss of Arv1,
explaining why these cells are hypersusceptible to azoles.
We are aware that reduced protein expression of certain Arv1 mutants may come into affect
when indicating whether or not there is an interaction between a specific Arv1 mutant and
Erg11. The interaction may be weak and below the detection level of western analysis. There is
also the probability that these mutants may be partially misfolded and this reduces their affin-
ity to Erg11. However, our data does show that certain Arv1 mutants that are expressed at
lower levels show different affinity for binding to Erg11.
In addition to lanosterol and unknown sterol intermediates, Scarv1 cells also accumulate
several ceramide species [26]. Whether ceramide accumulation plays a role in ScErg11 protein
instability or localization, and/or the appearance of any or all Scarv1 phenotypes, especially the
perturbed membrane morphology observed, is not known. Ceramide synthesis occurs in the
ER, the organelle whose morphology is distorted in Scarv1 cells [44]. Ceramide hyper-accumu-
lation and its mislocalization is seen in Niemann-Pick type C [45], Gaucher disease [46], and
cystic fibrosis [47] patients, and is a contributor to the progression of these diseases. It remains
to be examined if and how ceramide accumulation affects sterol metabolism.
The function(s) of Arv1 remains unresolved. There is accumulating evidence supporting
the idea that Arv1 may be a lipid-binding protein in mammalian and S. cerevisiae cells,
although this hypothesis has been challenged with regards to the yeast protein [28]. Concern-
ing CaArv1 function, our data strongly suggests that CaArv1 plays an important role in viru-
lence through its interaction with, and stabilization of, CaErg11. Thus, we believe that fungal
Arv1 may represent a new target for inhibiting the invasion of multiple pathogenic fungi, espe-
cially those found to be azole resistant.
Materials and methods
Strains, media, and miscellaneous microbial techniques
Yeast strains (W303α, S. cerevisiae; BWP7, C. albicans) (S1 & S2 Tables) were grown in either
YEPD (1% yeast extract, 2% bacto-peptone, 2% glucose), or synthetic minimal medium con-
taining 0.67% Yeast Nitrogen Base (Difco, Sparks, MD) supplemented with the appropriate
amino acids, adenine, and uracil. All antifungals were added to liquid cultures. Yeast transfor-
mation was performed using the procedure described by Ito et al., [48]. For routine propaga-
tion of plasmids, E. coli XL1-Blue cells were used and grown in LB medium supplemented
with ampicillin (150 μg/ml).
Plasmid construction and site-directed mutagenesis
The S. cerevisiae strains used in our studies were derived from W303-1A (MATa ura3 leu2 his3
trp1 ade2); the designated wild-type strain. pRS416-HA-URA3-CEN was used as a template to
generate plasmids expressing various ScArv1-HA and CaArv1-HA fusion proteins in S. cerevi-
siae. Protein expression in S. cerevisiae was driven from the endogenous ScARV1 promoter
(-1,000 to 0). pRS416-HA-URA3-CEN was selected for by plating on Ura- synthetic medium.
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All ScArv1 point mutants were generated using the Stratagene QuikChange1 Site-Directed
Mutagenesis Kit (Santa Clara, CA). Modifications to the PCR protocol included extending the
elongation cycle from 1m/kb to 2m/kb and increasing the number of cycles to 30.
pRS416-ScARV1-HA-URA3-CEN was used as a template for constructing point mutants.
CaArv1 point mutations were generated using the QuickChange Site Directed Mutagenesis
Kit (Stratagene) and pDDB78-HIS1-CaARV1 (pHIS1) as a template. Protein expression was
driven from the endogenous CaARV1 promoter.
The low copy centromeric plasmid pRS415-MYC-LEU2-CEN was used to express ScErg11-
MYC, CaErg11-MYC, and CaErg11Y132L F145L-MYC. Gene expression was driven by ScERG11
endogenous S. cerevisiae promoter sequences (-1,000 to 0). pRS415-MYC-LEU2-CEN was
selected for by growing cells in Leu- medium. When pRS416-ScARV1-HA-URA3-CEN and
pRS415-MYC-LEU2-CEN were co-expressed, cells were grown in Ura- Leu- double drop out
medium.
The pRS415-GAL1-GPD-MYC-LEU2 plasmid was used for high-level inducible expression
of ScErg-MYC and was selected for by growing strains in Leu- medium. The pCB74-TRP1-
2μm plasmid was used to overexpress GFP-Erg11, and was selected for by growing strains in
Trp- medium [26].
The C. albicans strain BWP17 (ura3/ura3 arg4/arg4 his1/his1) was used to generate all
strains; designated as the wild type strain. All C. albicans strains were grown in YEPD medium.
The Caarv1/Caarv1 strain was generated as previously described using the pGEM-URA3 and
pRS-ARG4ΔSpeI plasmids [25, 49, 50]. To integrate wild type and CaARV1 mutant alleles into
the Caarv1/Caarv1 strain, they were first PCR amplified and PCR fragments were cloned into
the disruption plasmid, pDDB78-HIS1 [51]. pDDB78-HIS1 plasmids containing CaArv1
mutant alleles were integrated into Caarv1/Caarv1 cells at the HIS1 locus. Integration was veri-
fied by PCR amplification through the HIS1 locus. Transformants were selected on medium
lacking uracil, arginine, and histidine. Integration was subsequently verified by PCR.
pRS-ARG4ΔSpeI was used for integration of the CaErg11Y132l F145L allele at a single CaErg11
allele. The Clp10 vector was use for integration at the URA3 locus [52]. Thus, all strains were
integrated with all selectable markers (URA3, ARG4, and HIS1) to eliminate auxotrophic
effects.
GFP-CaErg11 was integrated into various homozygous and heterozygous Caarv1/Caarv1
strains by allele integration at the CaARV1 locus using pGEM-URA3 and/or pRS-ARG4ΔSpeI
plasmids. Briefly, pCLP10-URA3 and pRS-ARG4ΔSpeI plasmids were constructed to contain
GFP-ERG11 sequences from pCB74, which included the GPD promoter and GFP sequences,
flanked by 70 bp of CaARV1 sequence. Integration results in the simultaneous disruption of
the CaARV1 locus with its replacement with the GFP-CaERG11 allele.
S. cerevisiae strains used for assaying UPR activation were generated by integrating the YIp
integrating vector, pRS406-UPRE-LacZ [53]. pRS406-UPRE-LacZ contains an UPRE promoter
sequence (CAGCGTG) fused to LacZ [38, 54]. pRS406-UPRE-LacZ integration was accom-
plished by vector digestion with Stu1 and transformation into cells. Positive clones were
selected on Ura- synthetic plates.
Protein extraction and immunoblotting
Total protein was isolated using the NaOH/TCA cell lysis/protein extraction method. Briefly,
cells were snap frozen in liquid N2, and lysed in 1.85M NaOH + 7.4% β-mercaptoethanol. Pro-
tein was precipitated from cell lysis solution in 25% trichloroacetic acid (TCA), washed with
acetone, and resuspended in 5% SDS in 0.1M Tris Base. Epitope-tagged Arv1 constructs were
detected using an anti-HA monoclonal antibody (clone 16B12) from Covance (Princeton, NJ).
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To detect 3HA tagged Arv1, Immobilon Western Chemiluminescent HRP substrate (Milli-
pore, Billerica, MA) was used as substrate for HRP-conjugated secondary mouse antibodies
(GE Healthcare, Waukesha, WI). Ponceau S staining and the Bradford method were used in
order to load equal amounts of protein in each well. ScPgk1 was used as a loading control.
To visualize Erg11-MYC, cell pellets were resuspended in lysis buffer (0.2M Tris Base,
0.39M (NH4)2SO4, 10mM MgSO4, 20% v/v Glycerol, 1mM EDTA, 1 mM AEBSP, Roche pro-
tease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), pH 7.9) and ice-cold glass
beads. Cells were then vortexed at 4˚C for 1 min and put on ice for 1 min; this was repeated for
a total of 10 times. The lysate was centrifuged at 3,000 X g for 5min. Supernatants were col-
lected and assayed for protein concentration using the Bradford reagent (Bio-Rad, Hercules,
CA). Erg11-MYC was detected using an anti-MYC monoclonal antibody (clone 9E10; 1:1000
dilution) from Covance (Princeton, NJ). Pgk1 was used as a loading control (anti-Pgk1, Invi-
trogen, Carlsbad, CA; 1:2,500 dilution). To detect Erg11-MYC and Pgk1, Pierce ECL Western
blotting substrate (Thermo Scientific, Waltham, MA) was used as a substrate for HRP-conju-
gated secondary mouse antibodies (GE Healthcare).
Minimal inhibitory concentration (MIC) assay
All strains were grown to exponential phase (0.5OD630) in the appropriate synthetic plasmid
selection medium. All proteins were expressed using low copy vectors and expression was
driven from the endogenous ARV1 promoter. 100 μl of 1x104 cells/ml of each strain were
plated into 96-well plates. 2-fold dilutions of antifungal drug were added and MICs were deter-
mined after 24 hr growth at 30˚C. MICs were characterized as the lowest concentration caus-
ing ~50% inhibition of growth at 24 hr, as measured at an OD630. To further validate the MIC
values, plate dilutions were also performed and viable cells were counted. We found either
method gave similar MIC results. All antifungal drugs were purchased from Sigma-Aldrich
(St. Louis, MO) and solubilized in DMSO.
Sterol composition analysis
Sterol analysis was performed as previously described [21].
Sterol localization analysis
The localization of unesterified sterol was visualized using filipin staining. Cells were grown to
exponential phase in synthetic medium. Cells were fixed with 3.7% formaldehyde for 10 min
at 23˚C under constant mixing. Fixed cells were washed twice with distilled water. Cells were
then incubated with 100μg/ml filipin (Sigma Chemicals) in the dark for 15 min at 23˚C. Filipin
fluorescence was visualized using a Leica DMR fluorescence microscope and UV optics.
mRNA stability assay
mRNA decay was determined using 3 μg/ml thiolutin as described [55].
ScErg11-MYC protein stability assay
Cells expressing ScErg11-MYC under the GAL1 promoter were grown to exponential phase in
2% raffinose. 2% galactose was added to cultures for 2 hr to induce ScErg11-MYC expression.
2% glucose was subsequently added and cells were collected at the indicated times.
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MG132 assays
Cells were grown to exponential phase. 35 μg/ml of cyclohexamide was added to all cultures.
Cells were then incubated with and without MG132 (75 mM) for 45 min. Cell pellets were col-
lected, and ScErg11 protein levels were determined by western analysis and immunoblotting
as described below.
Split-ubiquitin two-hybrid assay
The L40 (MATa trp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ) yeast strain was used for
two-hybrid studies. L40 contains HIS3 and LacZ reporter genes under the control of the lexA
promoter. A protein A-lexA-VP16 (PLV) fragment is released upon membrane protein–pro-
tein interaction, freeing it up to activate these promoters. The Cub vector (pCYC-BAIT-Cub-
PLV) and Nub vector (pADH-PREY-2HA-NubG) were used for expressing various Arv1 and
Erg11 proteins, and determining the level of protein-protein interaction. They were co-trans-
formed in L40 and double transformants were selected for and grown on Leu-Trp- medium to
maintain plasmid selection. The degree of protein-protein interaction was assayed by deter-
mining the robustness of growth on Leu-Trp-His- medium and level of β-galactosidase activity
over the negative control.
Co-immunoprecipitation assay
Cells were grown to exponential phase in the appropriate medium to maintain plasmid selec-
tion. Cells were pelleted and resuspended in lysis buffer (200 mM Tris-HCl, pH 8.0, 400 mM
(NH4)2SO4, 10 mM MgSO4, 20% v/v glycerol, 1 mM EDTA) plus protease inhibitors (Sigma).
1 mg of total protein was resuspended in 500 μl in buffer A. Cells were then incubated with the
appropriate antibody ((anti-HA monoclonal antibody (clone 16B12), 10 μl; anti-MYC mono-
clonal antibody (clone 9E10); 10 μl)) for 4 hr at 4˚C. 20 μl of Protein A agarose beads was then
added to the antibody/cell lysate slurry and incubated for 4 hr at 4˚ C. Complexes were pelleted
and washed several times with Co-IP buffer (10 mM HEPES, pH7.5, 200 mM NaCl, 5 mM
EDTA, 0.1% Nonidet P-40), and subsequently resuspended in treatment buffer, and proteins
were resolved using western analysis as described below.
ER retention studies
Cells were grown overnight in synthetic medium lacking uracil and transformed with
YCplac111-RTN2-GFP (RTN2 driven by its endogenous promoter in a CEN/ARS LEU2 vec-
tor). Transformants were selected on plates lacking uracil and leucine.
Fluorescence microscopy
For microscopy studies, cells were grown overnight in synthetic medium lacking uracil and
leucine and diluted to an OD600 of 0.15. Cells were grown for at least 7 h before microscopy.
Cells were imaged live at room temperature using a Zeiss AxioImager.Z2 epifluorescence
upright microscope with a 100X Plan-Apochromatic 1.4 numerical aperture (NA) objective
lens (Carl Zeiss Ltd, Jena, Germany). Images were recorded using a large chip sCMOS mono
camera for sensitive fluorescence imaging (ORCA Flash 4.0v2, Hamamatsu, Hamamatsu,
Japan), saved by Zeiss ZEN2.3 software (Blue edition, Carl Zeiss Ltd, Jena, Germany) and
exported to Adobe Photoshop (Adobe, San Jose, CA). Through-focus image series were decon-
volved with Volocity 6.3 (PerkinElmer, Waltham, MA) using calculated point-spread func-
tions. Stacks were then visualized using ImageJ 1.47v (NIH, Bethesda, MD) to manually detect
membrane aggregates at the periphery of the cell or increased cytosolic ER membranes in the
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cytosol at medial optical sections, by comparing the reporter fluorescence in the wild type cells
with mutant cells. Except for the wild type strain, which was used as a reference, quantification
of ER membranes was performed blindly.
UPRE-LacZ promoter driven β-galactosidase assay
β-galactosidase activity assays were performed as described using the substrate chlorophenol
red-β-D-galactopyranoside [38].
HAC1 mRNA splicing assay
Caarv1/Caarv1 Cells were grown to exponential phase. To measure the level of HAC1 mRNA
splicing, total RNA was obtained using a RNA extraction kit (Promega, USA) and was used to
generate a cDNA pool by reverse-transcription using an Oligo(dT)-primed RT reagent Kit
(Promega, USA). HAC1-5RT and HAC1-3RT primers were used to amplify these cDNA by
PCR (HAC1-5RT (TGAGGATGAACACCAAGAAGAA), and HAC1-3RT (TCAAAGTCCAACT
GAAATGAT) [39]. PCR products were separated by 3% agarose gel electrophoresis. CaARV1/
CaARV1 cells were treated with 2μ/ml tunicamycin for 2 hr as a control to activate the
unfolded protein response.
Disseminated candidiasis studies
The disseminated candidiasis mouse model was used for all virulence studies. Male BALB/c
mice (Jackson Labs) ages 6–8 weeks, weighing approximately 18-22g, housed in groups of as
many as four animals, were supplied food and water ad libitum. Cells were grown in YEPD
and injected via the tail vein with 200 μl of 1X106 cells/ml in 1X PBS. Infected animals were
monitored daily for up to 30 days post-infection and were considered moribund when they
had a ruffled coat, were hypothermic, and could no longer reach food or water. Animals were
euthanized by CO2 asphyxiation and survival times were recorded. All experiments were car-
ried out according to the NIH guidelines for the ethical treatment of animals.
Statistical analysis
Student’s t-test and one-way anova with Bonferroni post hoc were used to determine signifi-
cance of the data.
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